BRAF and neoplasm: There were no statistically significant differences in age, gender, site of melanoma, BRAF mutation status, stage IIIA, B or C status, lymph node status (N stage), the tumor size (T stage), ulceration status, tumor-infiltrating lymphocytes (TILs), and the Breslow depth (Table 1).